Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)
US$ in thousands
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The balance sheet reflects a period of substantial expansion in both the liability and equity bases from March 2021 through June 2026. Total liabilities and stockholders' equity grew from approximately $17.77 billion to $41.73 billion, indicating a significant increase in the overall size of the organization's capital structure.
- Liability Trends and Composition
- Total liabilities exhibited a consistent upward trajectory, rising from $5.79 billion in March 2021 to $10.02 billion by June 2026. This increase is primarily attributed to the growth in current liabilities, which escalated from $3.22 billion to $5.53 billion. Within this category, accounts payable showed a marked increase, particularly in the latter half of the period, ending at $1.16 billion. Accrued expenses and other current liabilities also trended upward, moving from $1.49 billion to $2.97 billion.
- Noncurrent liabilities increased from $2.58 billion to $4.49 billion. A critical observation is the stability of long-term debt, which remained almost stagnant throughout the five-year period, hovering around $1.98 billion. The growth in noncurrent liabilities was instead driven by "Other noncurrent liabilities," which rose from $571.5 million to $2.28 billion, suggesting an increase in long-term obligations not related to traditional bank debt or bonds.
- Stockholders' Equity and Capital Accumulation
- Stockholders' equity grew aggressively, increasing from $11.98 billion in March 2021 to $31.71 billion by June 2026. The primary driver of this growth was retained earnings, which rose from $12.01 billion to $37.62 billion. This suggests a high capacity for internal capital generation and strong profitability over the analyzed period.
- A significant trend is observed in the Treasury Stock account, which expanded from a negative value of $6.94 billion to $20.57 billion. This indicates a consistent and aggressive share repurchase program, effectively offsetting a portion of the gains in retained earnings and reducing the total number of shares outstanding.
- Additional paid-in capital also saw a steady increase, rising from $6.89 billion to $14.70 billion, reflecting additional equity contributions or adjustments to the equity base.
- Financial Solvency and Leverage Insights
- The growth in stockholders' equity significantly outpaced the growth in total liabilities. While total liabilities increased by approximately 73%, stockholders' equity increased by approximately 165% over the same period. This shift indicates a strengthening of the solvency position and a decrease in the company's reliance on external leverage.
- The stability of the long-term debt profile, coupled with the massive accumulation of retained earnings, suggests a conservative approach to debt financing and a preference for funding operations and growth through internal cash flows.